The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Revolution Medicines, Inc. of shares of its common stock for up to an aggregate amount of $500 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

Based in Redwood City, California, Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Beth LeBow and associates Bex Childress and Dove Barbanel. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post